Abstract
Background For young patients with depression, electroconvulsive therapy (ECT) is highly effective but causes acute cognitive side effects. We designed a new i-HECT therapy combines ECT with low-charge electrotherapy (LCE) and individual symptom monitoring to reduce cognitive impairments.
Methods i-HECT comprised two treatments: ECT and LCE. ECT utilized an energy set of 1.5 times the seizure threshold (ST), while LCE was set at 0.5 ST. The initial session employed ECT. Subsequent sessions involved ECT or LCE, depending on whether meeting the ECT-LCE transition criteria (MADRS total score < 22 or ≥ 50% reduction), assessed after each session.
Results The intention-to-treat analysis revealed an 80.4% response rate and a 58.7% remission rate (Hedges’ g = 3.29). Notably, both subjective and objective cognitive functions significantly improved post-i-HECT treatments and during the 3-month follow-up periods.
Conclusion The i-HECT protocol may provide a rapid antidepressant treatment option with cognitive benefits for young depression patients.
Highlights
Designed a novel but simple ECT protocol, i-HECT, for young depression patients.
The trial employed Simon’s optimal two-stage design with a high power of 0.95.
The i-HECT rapidly improved both depression symptoms and cognitive functions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2100045682
Funding Statement
This work was supported by grant from the Science and Technology Program of Huizhou (Grant No. 2021SC010311001 (Baijian Tan) and 2022CQ010013 (Lun Zeng)) and the Guangdong Medical Research Foundation (Grant No.A2022333 (Lun Zeng)). This work has not received funding/assistance from any commercial organizations. The funding source had no roles in the design of this study and will not have any roles during the execution, analyses, interpretation of the data, or decision to submit results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This single-arm trial employed a Simon's optimal two-stage design with a 3-month follow-up duration, conducted at the Second People's Hospital of Huizhou in accordance with the Declaration of Helsinki. The Human Ethics Committee of the Hospital approved the protocol. Patients and their legal guardians can withdraw at any time for any reason.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest The authors declare that there is no conflict of interest in this work.
Funding This work was supported by grant from the Science and Technology Program of Huizhou (Grant No. 2021SC010311001 (Baijian Tan) and 2022CQ010013 (Lun Zeng)) and the Guangdong Medical Research Foundation (Grant No.A2022333 (Lun Zeng)). This work has not received funding/assistance from any commercial organizations. The funding source had no roles in the design of this study and will not have any roles during the execution, analyses, interpretation of the data, or decision to submit results.
Data Availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
